Last reviewed · How we verify
Second Asthma Controller Medication
At a glance
| Generic name | Second Asthma Controller Medication |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma (PHASE4)
- Telehealth Education for Asthma Connecting Hospital and Home (NA)
- Real-time Remote Asthma Monitoring Through Smartphone Voice Analysis
- Evaluation of Dupilumab in Children With Uncontrolled Asthma (PHASE3)
- Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma (NA)
- Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma (PHASE3)
- Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest) (PHASE3)
- A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Second Asthma Controller Medication CI brief — competitive landscape report
- Second Asthma Controller Medication updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI